Media headlines about Chiasma (NASDAQ:CHMA) have been trending somewhat negative on Friday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Chiasma earned a news sentiment score of -0.01 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.94268226072 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

NASDAQ:CHMA traded up $0.12 on Friday, reaching $2.45. The stock had a trading volume of 63,972 shares, compared to its average volume of 49,803. Chiasma has a 12-month low of $1.20 and a 12-month high of $2.95.

Chiasma (NASDAQ:CHMA) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.36).

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Recommended Story: What kind of dividend yield to CEF’s pay?

Insider Buying and Selling by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with's FREE daily email newsletter.